Ginkgo biloba / ROS Cancer Research Results

Ginkgo biloba
│
├── Ginkgo biloba leaf / generic GBE
│
├── Standardized extracts
│   └── EGb 761
│
├── Terpene lactones
│   ├── Ginkgolide A
│   ├── Ginkgolide B        ← separate product
│   ├── Ginkgolide C
│   └── Bilobalide          
│
├── Biflavonoids
│   ├── Ginkgetin           ← separate product
│   ├── Isoginkgetin       
│   ├── Bilobetin           
│   ├── Sciadopitysin
│   └── Amentoflavone       
│
├── Flavonols
│   ├── Quercetin
│   ├── Kaempferol
│   └── Isorhamnetin
│
└── Alkylphenolic acids
    └── Ginkgolic acids     ← separate product



**Issue with EGb761(Tebonin) vs other extracts: 
| Feature                 | EGb 761                              | Typical Amazon.ca Ginkgo          |
| ----------------------- | ------------------------------------ | --------------------------------- |
| Source                  | Dried Ginkgo leaves                  | Usually dried leaves              |
| Flavone glycosides      | ~24%                                 | Often 24%, sometimes unspecified  |
| Terpene lactones        | ~6%                                  | Sometimes 6%; often not stated    |
| Ginkgolides A/B/C       | Controlled profile                   | Usually not individually verified |
| Bilobalide              | Controlled profile                   | Usually not stated                |
| Ginkgolic acids         | **<5 ppm**                           | Frequently not stated             |
| Extract/process         | Defined proprietary process          | Manufacturer-specific             |
| Batch consistency       | Pharmaceutical-style standardization | Variable                          |
| Human dementia evidence | Extensive                            | Usually indirect extrapolation    |
| Equivalent to EGb 761?  | Yes                                  | **Not automatically**             |
** Ginkgolic Acids can have associated risks of liver and kidney damage 

Ginkgo biloba — a medicinal tree whose pharmacologically relevant preparations are primarily standardized extracts of dried leaves. It is classified as a botanical/herbal medicinal product rather than a single-molecule drug. Common abbreviations include GBE or GLE for Ginkgo biloba leaf extract; EGb 761 is a specific, extensively studied standardized extract containing approximately 24% flavonol glycosides and 6% terpene lactones, principally ginkgolides and bilobalide. Standardized medicinal extracts should be distinguished from crude leaf, seeds, and isolated ginkgolic acids; ginkgolic acids are potentially toxic constituents that are substantially removed during manufacture of high-quality standardized extracts. Neurocognitive and vascular evidence is substantially stronger than evidence for anticancer use.

Primary mechanisms (ranked):

1. Redox and mitochondrial modulation, including direct radical scavenging and enhancement of endogenous antioxidant defenses; predominantly cytoprotective in neural and normal tissues.
2. Platelet-activating factor antagonism by ginkgolides with effects on platelet activation, vascular tone, microcirculation, and inflammatory signaling.
3. Mitochondrial stabilization and suppression of inappropriate apoptotic signaling in neurons, including reduced cytochrome-c release and caspase activation.
4. Anti-inflammatory signaling involving reduced NF-κB-associated inflammatory activity and cytokine production in multiple preclinical models.
5. Modulation of neuronal survival, synaptic function, neurotransmission, and amyloid-associated toxicity relevant to neurodegeneration.
6. Antiproliferative and pro-apoptotic effects in selected cancer models, particularly from flavonoid constituents such as quercetin and kaempferol; these effects remain preclinical.
7. Anti-angiogenic signaling through SHP-1-associated inhibition of the Raf/MEK/ERK pathway in experimental vascular models.
8. Chemosensitization in selected experimental tumor systems, including increased 5-fluorouracil sensitivity; clinical oncology relevance is unestablished.

Bioavailability / PK relevance: Ginkgo leaf extract is a multicomponent preparation rather than a concentration-defined single compound. Terpene lactones including ginkgolides A, B and C and bilobalide reach systemic circulation after oral standardized extracts, while flavonoid glycosides undergo extensive metabolism to conjugated metabolites. Extract composition strongly affects pharmacology. At recommended standardized-extract doses around 120–240 mg/day, clinically important CYP-mediated interactions appear substantially smaller than suggested by many high-concentration in-vitro experiments, although medication interactions remain possible.

In-vitro vs systemic exposure relevance: Many anticancer experiments use whole extracts or isolated flavonoids at concentrations considerably above concentrations achievable for the corresponding unconjugated constituents after ordinary oral Ginkgo supplementation. Cancer-cell findings involving isolated ginkgolic acid should not be treated as equivalent to effects of medicinal EGb 761 because standardized extracts intentionally contain very little ginkgolic acid. Consequently, direct extrapolation of most cancer-cell cytotoxicity studies to oral Ginkgo use is weak.

Clinical evidence status: Cancer: preclinical only; no established anticancer efficacy and no validated role as cancer therapy. Dementia: human RCT evidence exists, particularly for standardized EGb 761 at 240 mg/day; the 2026 Cochrane assessment concludes that patients with dementia may obtain small-to-moderate improvements in global status, cognition and activities of daily living at approximately six months, while evidence for mild cognitive impairment shows little or no benefit. Ginkgo does not prevent dementia in cognitively normal older adults or those with MCI. It should therefore be regarded as a possible symptomatic adjunct in established dementia rather than a demonstrated disease-preventing or disease-modifying therapy.

Safety / formulation constraint: Standardized leaf extract is generally tolerated at medicinal doses, but headache, dizziness and gastrointestinal effects occur. Bleeding events have been reported, and regulatory authorities advise caution or avoidance with anticoagulants, other products affecting coagulation, and around surgery. Pregnancy is contraindicated under the EMA medicinal-use monograph because platelet aggregation may be impaired. Raw or inadequately processed Ginkgo preparations are not interchangeable with standardized medicinal extracts. High-dose animal carcinogenicity findings exist for a non-EGb-761 Ginkgo extract, but their relevance to standard human medicinal dosing remains uncertain.

Ginkgo biloba — Cancer-Relevant Mechanisms

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr

Ginkgo biloba — Alzheimer’s disease: AD and dementia are substantially more clinically relevant indications for standardized Ginkgo leaf extract than cancer. EGb 761 has antioxidant, mitochondrial, vascular, anti-inflammatory and neuroprotective actions and has been studied in multiple randomized dementia trials. The most current high-level evidence indicates possible small-to-moderate symptomatic benefit in established dementia at approximately six months, but little or no benefit in mild cognitive impairment and no demonstrated prevention of incident Alzheimer’s disease. The evidence therefore supports classification as a possible symptomatic adjunct rather than a proven disease-modifying AD treatment.

Primary mechanisms (ranked):

1. Mitochondrial protection and oxidative-stress reduction.
2. Neurovascular and microcirculatory effects including PAF antagonism.
3. Suppression of pathological neuronal apoptosis and preservation of mitochondrial membrane integrity.
4. Neuroinflammatory modulation.
5. Reduction of Aβ-associated cellular toxicity and protein-aggregation effects in preclinical systems.
6. Synaptic and neurotransmitter modulation supporting neuronal function.

Clinical evidence status: RCT-supported symptomatic effect in established dementia, but heterogeneous and generally modest; little or no demonstrated benefit for MCI and no established dementia-prevention effect. Most positive modern trials evaluated specific standardized extracts, particularly EGb 761 at 240 mg/day, so results should not automatically be extrapolated to arbitrary commercial Ginkgo products.

Ginkgo biloba — Alzheimer’s Disease Mechanisms

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr